 | |
| Clinical data | |
|---|---|
| Other names | TAK-831 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C13H11F3N2O2 |
| Molar mass | 284.238 g·mol−1 |
Luvadaxistat is an experimental drug that works as a D-amino acid oxidase inhibitor and is supposed to increase NMDA receptor functionality.[1] It is developed to treat Friedrich ataxia[2] and negative symptoms of schizophrenia.[3][4][5]
References[edit]
- ^ O’Donnell, Patricio; Dong, Cheng; Murthy, Venkatesha; Asgharnejad, Mahnaz; Du, Xiaoming; Summerfelt, Ann; Lu, Hong; Xu, Lin; Wendland, Jens R.; Dunayevich, Eduardo; Buhl, Derek L.; Litman, Robert; Hetrick, William P.; Hong, L. Elliot; Rosen, Laura B. (June 2023). "The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial". Neuropsychopharmacology. 48 (7): 1052–1059. doi:10.1038/s41386-023-01560-0. ISSN 1740-634X. PMC 10018616. PMID 36928351.
- ^ Wang, Hao; Norton, Jonathan; Xu, Lin; DeMartinis, Nicholas; Sen, Rohini; Shah, Ankit; Farmer, Jennifer; Lynch, David (June 2021). "Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia". Annals of Clinical and Translational Neurology. 8 (6): 1343–1352. doi:10.1002/acn3.51373. PMC 8164851. PMID 34018342.
- ^ Fradley, Rosa; Goetghebeur, Pascal; Miller, David; Burley, Russell; Almond, Sarah; Gruart i Massó, Agnès; Delgado García, José M.; Zhu, Bin; Howley, Eimear; Neill, Jo C.; Grayson, Ben; Gaskin, Philip; Carlton, Mark; Gray, Ian; Serrats, Jordi; Davies, Ceri H. (October 2023). "Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia". Neurochemical Research. 48 (10): 3027–3041. doi:10.1007/s11064-023-03956-2. PMC 10471729. PMID 37289348.
- ^ Veselinović, Tanja; Neuner, Irene (August 2022). "Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia". CNS Drugs. 36 (8): 819–858. doi:10.1007/s40263-022-00935-z. PMC 9345797. PMID 35831706.
- ^ Kuo, Chien-Yi; Lin, Chieh-Hsin; Lane, Hsien-Yuan (November 2022). "Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research". CNS Drugs. 36 (11): 1143–1153. doi:10.1007/s40263-022-00959-5. PMID 36194364. S2CID 252694226.